EDCTP

Batavia Biosciences announced last week that it has successfully manufactured shots for Phase 1 trials in Africa and the U.S. of the recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine being developed by the International AIDS Vaccine Initiative (IAVI).

The Dutch company, which initially partnered with IAVI in 2018, said it manufactured rVSVΔG-LASV-GPC using its HIP-Vax platform, which “enables the production of high volumes of vaccine doses in a small…

The International AIDS Vaccine Initiative (IAVI) announced Monday $27.4 million in additional funding to conduct Phase 2b trials of its recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine (rVSVΔG-LASV-GPC) in Liberia, Nigeria and Sierra Leone.

According to the press release, the European & Developing Countries Clinical Trials Partnership and the Coalition for Epidemic Preparedness Innovations (CEPI) provided the grant, which builds on an earlier $10.4…

Mentions:

The Pediatric Praziquantel Consortium announced new funding last month from Japan’s Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership.

The separate awards—worth a combined $9.3 million—will fund the ADOPT program, dedicated to “wide acceptance and equitable access” for a child-friendly dispersible tablet formulation of schistosomiasis drug praziquantel.

With backers including Astellas, Farmanguinhos and Merck…

Announcing a $49 million, five-year grant, the European & Developing Countries Clinical Trials Partnership (EDCTP)—along with Medicines for Malaria Venture (MMV), Novartis and other partners—pledged to support the PAMAfrica research consortium in developing new malaria treatments.

The funds will back clinical trials in three areas: testing new combinations of compounds to treat drug-resistant uncomplicated malaria; evaluating Novartis’ cipargamin (KAE609) for severe malaria; and…

GSK announced yesterday that it has licensed its novel subunit TB vaccine to the Gates Medical Research Institute (Gates MRI) to allow continued development of the candidate for potential use in low-income countries with high disease burdens.

In HIV-negative adults with latent infection, M72/AS01E demonstrated overall efficacy of 50 percent in reducing progression to active TB over three years, according to Phase 2b results published in October 2019.

However, GSK did not disclose…

The European & Developing Countries Clinical Trials Partnership (EDCTP) announced two vaccine awards over the past week.

First, it gave $20 million to the P. falciparum transmission-blocking vaccine (PfTBV) consortium to test and compare three vaccines: two malaria vaccines developed by Denmark’s Statens Serum Institute and another from the U.S. National Institutes of Health. The project started in January of this year and will run until mid-2024 in Burkina Faso, Mali, Guinea and…

The European & Developing Countries Clinical Trials Partnership (EDCTP) announced this week it will award $11.3 million over five years to support late-stage clinical trials of a next-generation antimalarial comprised of KAF156 (ganaplacide) and lumefantrine in a new, once-daily formulation. Burkina Faso, Gabon, Mali and Niger will host trial sites of the WANECAM 2 study; the funding will also strengthen in-country clinical research infrastructure and capabilities, according to an EDCTP…

Mentions: